

### Antibiotic Usage

Overall, 55 of the 56 patients had received antibiotics prior to the isolation of *A baumannii* from a clinical specimen; 54 had received a  $\beta$ -lactam antibiotic and 18 had received an aminoglycoside. The 1 patient who had not received antibiotic therapy grew a multiresistant *A baumannii* isolate from urine.

Nine patients who never received imipenem, amikacin, or tobramycin during their hospital stay contributed 18 initial and subsequent clinical isolates. Nine of the 18 isolates were resistant to imipenem, and nine were resistant to both aminoglycosides. In contrast, overall resistance rates for clinical isolates from the 56 patients were 35% for imipenem and 28% for aminoglycoside.

No isolate became more susceptible to antibiotics with time. Of the 34 subsequent clinical isolates from 29 patients, 10 displayed greater resistance than the initial isolates, and 6 of these had become panresistant.

### DISCUSSION

The ability of *A baumannii* to acquire antimicrobial resistance and its propensity for nosocomial colonization of the gastrointestinal tract have been well described.<sup>8</sup> In this study, one half of the patients were colonized in either the gastrointestinal tract or on the skin. Colonization developed rapidly, most often in the first week after *A baumannii* was isolated from a clinical site, and was persistent in 58% of patients. Susceptibility patterns of the colonizer and clinical isolates differed for 29% of patients. Four patients, despite having susceptible clinical isolates, harbored a multiresistant or panresistant isolate, either on the skin or in the gastrointestinal tract, that would have been undetected without surveillance. Both clinical and colonizer isolates had varying susceptibility patterns during this study period. The discordance and heterogeneity of isolates make the efforts of infection control more complex, as isolates may differ from site to site, as well as through time. Prior antibiotic exposure did not predict resistance patterns.

These data suggest that, in patients with a clinical isolate of *A baumannii*, gastrointestinal and skin colonization should be ascertained and then monitored for changing susceptibility patterns. Transmission-based infection control methods, such as contact isolation and isolation of infected or colonized patients, may be the most effective strategy.

From the Department of Medicine (Drs. Dy, Nord, Kislak) and the Department of Laboratories (Dr. LaBombardi), St Vincent's Hospital and Medical Center, New York City, New York.

Address reprint requests to Jill A. Nord, MD, St Vincent's Hospital and Medical Center, 153 West 11th St, Cronin 1003, New York, NY 10011.

98-OA-109. Dy ME, Nord JA, LaBombardi VJ, Kislak JW. The emergence of resistant strains of *Acinetobacter baumannii*: clinical and infection control implications. *Infect Control Hosp Epidemiol* 1999;20:565-567.

### REFERENCES

- Bergogne-Berezin E, Joly-Guillou ML. Hospital infection with *Acinetobacter* spp: an increasing problem. *J Hosp Infect* 1991;18(suppl A):250-255.
- Contant J, Kemeny E, Oxley C, Perry E, Garber G. Investigation of an outbreak of *Acinetobacter calcoaceticus* var *anitratus* infections in an adult intensive care unit. *Am J Infect Control* 1990;18:288-291.
- Go ES, Urban C, Burns J, Kreiswirth B, Eisner W, Mariano N, et al. Clinical and molecular epidemiology of *Acinetobacter* infections sensitive only to polymyxin B and sulbactam. *Lancet* 1994;344:1329-1332.
- Cefai C, Richards J, Gould FK, McPeake P. An outbreak of *Acinetobacter* respiratory tract infection resulting from incomplete disinfection of ventilatory equipment. *J Hosp Infect* 1990;15:177-182.
- Sherertz RJ, Sullivan ML. An outbreak of infections with *Acinetobacter calcoaceticus* in burn patients: contamination of patients' mattresses. *J Infect Dis* 1985;151:252-258.
- Patterson JE, Vecchio J, Pantelick EL, Farrel P, Mazon D, Zervos MJ, et al. Association of contaminated gloves with transmission of *Acinetobacter calcoaceticus* var *anitratus* in an intensive care unit. *Am J Med* 1991;91:479-483.
- Allen KD, Green HT. Hospital outbreak of multiresistant *Acinetobacter anitratus*: an airborne mode of spread? *J Hosp Infect* 1987;9:110-119.
- Timsit JF, Garrait V, Missot B, Goldstein FW, Renaud B, Carlet J. The digestive tract is a major site for *Acinetobacter baumannii* colonization in intensive care unit patients. *J Infect Dis* 1993;168:1336-1337.
- Buxton AE, Anderson RL, Werdegar D, Atlas E. Nosocomial respiratory tract infection and colonization with *Acinetobacter calcoaceticus*: epidemiologic characteristics. *Am J Med* 1978;65:507-513.
- Corbella X, Pujol M, Ayats J, Sendra M, Ardanuy C, Dominique MA, et al. Relevance of digestive tract colonization in the epidemiology of nosocomial infections due to multiresistant *Acinetobacter baumannii*. *Clin Infect Dis* 1996;23:329-334.

## Satellite Broadcast: Biological Warfare

Gina Pugliese, RN, MS  
Martin S. Favero, PhD

Knowledge about the extensive biological weapons programs in other countries and numerous recent bioterrorism threats have increased concern regarding the medical management of biological agent casualties. Military and civilian medical and public health professionals must

become proficient in recognizing that a biological attack has occurred, activating the appropriate agencies and personnel to investigate the event, treating the casualties, and preventing the spread of the agent. A live, interactive 3-day satellite broadcast will educate health professionals about the proper medical response in the event of an intentional biological agent release. Experts from the US Army Medical Research Institute of

Infectious Disease (USAMRIID), the CDC, and other organizations will present this program at no charge. The program will be broadcast live on September 21, 22, and 23, from 12:30 PM to 4:40 PM EST, with a taped rebroadcast on October 2 and 3 from 11:30 AM to 5:30 PM. More information about this program and registration is available at [www.biomedtraining.org](http://www.biomedtraining.org), or call Mr. Darren Gerlach at (301) 619-7515.